Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human... see more

Recent & Breaking News (NYSE:MRK)

Benzinga's M&A Chatter for Wednesday August 3, 2016

Benzinga.com  August 3, 2016

Terms Of The Trade: Dogs Of The Dow Investing Strategy

Benzinga.com  August 3, 2016

Benzinga's M&A Chatter for Tuesday August 2, 2016

Benzinga.com  August 2, 2016

Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Business Wire August 2, 2016

Merck's Q2 Good, But Not Good Enough, Says BMO

Benzinga.com  August 1, 2016

La Commission européenne délivre une autorisation de mise sur le marché pour le ZEPATIER™ (elbasvir/grazoprevir) fabriqué par la société MSD pour le traitement des patients atteints d’une infection chronique par le virus de l’hépatite C

Business Wire July 29, 2016

Weak GDP Data, Plunging Oil Renew Questions About Strength Of Economy

Benzinga.com  July 29, 2016

A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of GDP Report

Benzinga.com  July 29, 2016

Investors Greet Merck Q2 Results As Key Launches Help Beat

Benzinga.com  July 29, 2016

NextEra Energy Agrees To Buy Energy Future Holdings' Stake In Oncor Electric Delivery Company

Benzinga.com  July 29, 2016

Merck Announces Second-Quarter 2016 Financial Results

Business Wire July 29, 2016

12 Stocks You Should Be Watching Today

Benzinga.com  July 29, 2016

Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

Canada NewsWire July 28, 2016

Merck Announces Fourth-Quarter 2016 Dividend

Business Wire July 26, 2016

Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine

Benzinga.com  July 25, 2016

NewLink Genetics Announces Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)

GlobeNewswire July 25, 2016

Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)

Business Wire July 25, 2016

Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS

Benzinga.com  July 22, 2016

Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...

Business Wire July 22, 2016

Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs

Business Wire July 21, 2016
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested